When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ALPMF - Astellas Pharma's DNA vaccine candidate flunks late-stage study in CMV-positive HSCT patients; licensor Vical down 22% premarket
Astellas Pharma Inc
Astellas Pharma (OTCPK:ALPMF) and licensor Vical (NASDAQ:VICL) announce that Astellas' investigational DNA vaccine candidate, Orphan Drug-tagged ASP0113, failed to achieve the primary endpoint and secondary endpoints in a Phase 3 clinical trial, HELIOS, in cytomegalovirus (CMV)-seropositive hematopoietic stem cell transplant (HSCT) recipients.
More news on: Astellas Pharma, Inc., Vical Incorporated, Healthcare stocks news, Stocks on the move,